

AUNP-12 TFA

Cat. No.:	HY-P1812A
Molecular Formula:	C ₁₄₂ H ₂₂₆ N ₄₀ O ₄₈ ·C ₂ HF ₃ O ₂
Molecular Weight:	3375.57
Sequence Shortening:	H-SNTSESFKF(H-SNTSESF)RVTQLAPKAQIKE-NH2
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

BIOLOGICAL ACTIVITY

Description	AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1] .
IC ₅₀ & Target	PD-1 signaling pathway ^[1]
In Vitro	NP-12 TFA displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions ^[1] . NP-12 TFA rescues the proliferation in the mouse splenocyte assay system with average EC ₅₀ values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively ^[1] . NP-12 TFA is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC ₅₀ values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA